At the January 2026 conference, Axogen’s leadership team, led by President and CEO Mike Dale and CFO Lindsey Hartley, outlined the company’s mission to restore peripheral nerve function and improve patient quality of life. Dale, in his first 18 months at the helm, emphasized expanding market access through new reimbursement codes secured in late 2025, which are expected to unlock an additional 10,000 procedures annually in the U.S. He also detailed progress on the novel Avance® Nerve Graft portfolio, reporting a year-over-year revenue increase of 22% in the fourth quarter of 2025, driven by surgeon adoption at 120 centers nationwide. CFO Hartley highlighted a strengthened balance sheet, with cash and short-term investments rising by $15 million since mid-2025 and gross margins improving by 250 basis points to 58%. The team reiterated guidance for full‐year 2026 revenue growth in the mid‐teens percentage range, supported by international expansion efforts in Europe and Latin America where distribution partnerships now cover 15 additional countries.

On December 10, 2025, CEO Mike Dale sold 25,000 shares of Axogen common stock directly, generating proceeds of $750,000. This transaction represented 28.24% of his direct holdings prior to the sale, reducing his stake to 63,537 shares, or approximately 0.14% of shares outstanding. The sale followed a six-month lockup expiration tied to performance milestones and was executed through a standard Rule 10b5-1 trading plan established in September 2025. Company insiders note that the disposal was intended to fund personal tax obligations and diversified investment allocations, with no planned impact on Axogen’s strategic initiatives or Dale’s long-term commitment to the business.